加拿大安大略省接受血清学检测个体的麻疹血清流行率
研究将2014-2016年安大略省349451名接受麻疹IgG血清学检测者的数据与健康行政数据库链接,采用横断面设计测量麻疹IgG血清流行率。按≥275 mIU/mL阈值,血清流行率为83.5%(95%CI 83.4-83.6%),低于90-95%群体免疫阈值;按>120 mIU/mL阈值则为97.1%(95%CI 97.0-97.1%)。血清流行率随年龄和移民身份显著变化,青少年、年轻成人及年轻移民的血清阴性率最高。
要点
- 按≥275 mIU/mL阈值,麻疹血清流行率为83.5%(95%CI 83.4-83.6%),低于90-95%群体免疫阈值。
- 按>120 mIU/mL阈值,血清流行率为97.1%(95%CI 97.0-97.1%)。
- ≥275 mIU/mL阈值下,12-19岁青少年血清流行率最低(75.3%;95%CI 74.8-75.7%),20-29岁年轻成人次低(75.8%;95%CI 75.5-76.1%),≥50岁最年长队列最高(96.9%;95%CI 96.8-97.0%)。
核心结论
- 麻疹保护性相关指标的不确定性使血清流行率数据解读复杂化,难以判断该便利样本是否受到足够保护以预防未来暴发。
- 麻疹血清流行率随年龄和移民身份显著变化,血清阴性(<275 mIU/mL)最高见于青少年、年轻成人和年轻移民。
- 面对持续的国际麻疹输入和部分人群的免疫缺口,安大略省维持麻疹消除可能具有挑战性。
研究设计与样本
- 研究将2014-2016年安大略省349451名接受麻疹IgG血清学检测个体的数据与健康行政数据库链接,采用横断面设计测量麻疹IgG血清流行率。
- 研究估计总体血清流行率并按社会人口学因素分层。
主要发现
- 使用制造商推荐的≥275 mIU/mL阈值,麻疹血清流行率为83.5%(95%CI 83.4-83.6%),低于90-95%群体免疫阈值。
- 使用常被引用的>120 mIU/mL阈值,血清流行率为97.1%(95%CI 97.0-97.1%)。
- 使用≥275 mIU/mL阈值,12-19岁青少年血清流行率最低(75.3%;95%CI 74.8-75.7%),20-29岁年轻成人为75.8%(95%CI 75.5-76.1%),≥50岁最年长队列最高(96.9%;95%CI 96.8-97.0%)。
- 使用较低保护阈值>120 mIU/mL时,未观察到按年龄的血清流行率大幅差异。
- 在1985年或之后出生者中,移民的血清流行率(≥275 mIU/mL)为71.0%(95%CI 70.6-71.5%),低于加拿大出生者的77.8%(95%CI 77.6-78.1%)。
局限性
- 麻疹确切保护性相关指标的不确定性使血清流行率数据在评估该便利样本是否受到足够保护以预防未来暴发时解读复杂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Canada eliminated measles in 1998, but the risk of outbreaks remains due to sub-optimal vaccine coverage and imported cases. To address limitations of vaccine coverage data, we measured measles seroprevalence among a convenience sample of individuals serologically tested in Ontario, Canada. METHODS: We linked measles IgG serology data from 349,451 individuals tested during 2014-2016 to health administrative databases and used a cross-sectional design to measure measles IgG seroprevalence. We estimated seroprevalence overall and by sociodemographic factors. FINDINGS: Using the manufacturer-recommended threshold of ≥275 mIU/mL, measles seroprevalence was 83.5 % (95% CI, 83.4-83.6 %), below the 90-95 % herd immunity threshold. However, using the often cited >120 mIU/mL threshold, seroprevalence was 97.1 % (95% CI, 97.0-97.1 %). Using a threshold of ≥275 mIU/mL, seroprevalence varied by age, with the lowest observed among adolescents aged 12-19 years (75.3 %; 95% CI, 74.8-75.7 %) and young adults aged 20-29 years (75.8 %; 95% CI, 75.5-76.1 %), and highest among the oldest cohorts aged ≥50 years (96.9 %; 95% CI, 96.8-97.0 %). When using a lower threshold of protection (>120 mIU/mL), large differences in seroprevalence by age were not observed. Among individuals born in or after 1985, immigrants had lower seroprevalence (≥275 mIU/mL) (71.0 %; 95% CI, 70.6-71.5 %) compared to those born in Canada (77.8 %; 95% CI, 77.6-78.1 %). INTERPRETATION: The uncertainty of the exact correlate of protection for measles complicates the interpretation of seroprevalence data when assessing whether this convenience sample of individuals serologically tested for measles is adequately protected to prevent future outbreaks. Measles seroprevalence varied significantly by age and immigrant status, with highest seronegativity (<275 mIU/mL) observed among adolescents, young adults, and young immigrants. It is possible that sustaining measles elimination in Ontario will be challenging in the face of ongoing measles importations from abroad, and immunity gaps in some population groups.
引用
- Ariyarajah A, Crowcroft NS, Brown KA, et al. Measles seroprevalence among individuals serologically tested in Ontario, Canada. Vaccine. 2025. PMID: 40651306. doi:10.1016/j.vaccine.2025.127446
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。